Exosomal Hsa-miR-151a-3p and Hsa-miR-877-5p Are Potential Novel Biomarkers for Predicting Bone Metastasis in Lung Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Jan 5

PMID 38180107

Authors

Kun Zhao

Changji Jia

Jin Wang

Weiye Shi

Xiaoying Wang

Yan Song

Changliang Peng

Affiliations

Soon will be listed here.

Abstract

Exosomal miRNAs (exo-miRNAs) have arisen as novel diagnostic biomarkers for various cancers. However, few reports on exo-miRNAs related to bone metastasis (BM) in lung cancer exist. This study aims to screen out key exo-miRNAs and estimate their prognostic values for predicting BM in lung cancer. The differentially expressed exo-miRNAs between the highly-metastatic (95D) and lowly-metastatic (A549) human lung cancer cell lines were comprehensively analyzed using high-throughput sequencing followed by bioinformatic analyses. 29 candidate exo-miRNAs were identified, and 101 BM-related target genes were predicted. Enrichment analysis revealed that these target genes were mainly involved in regulating transcription and pathways in cancer. An exosomal miRNA-mRNA regulatory network consisting of 7 key miRNAs and 10 hub genes was constructed. Further function analysis indicated that these 10 hub genes were mainly enriched in regulating cancer's apoptosis and central carbon metabolism. The survival analysis indicated that 7 of 10 hub genes were closely related to prognosis. Mutation analysis showed that lung cancer patients presented certain genetic alterations in the 7 real hub genes. GSEA for a single hub gene suggested that 6 of 7 real hub genes had close associations with lung cancer development. Finally, ROC analysis revealed that hsa-miR-151a-3p and hsa-miR-877-5p provided high diagnostic accuracy in discriminating patients with bone metastasis (BM+) from patients without bone metastasis (BM-). These findings provided a comprehensive analysis of exo-miRNAs and target genes in the regulatory network of BM in lung cancer. In particular, hsa-miR-151a-3p and hsa-miR-877-5p may be novel biomarkers for predicting BM in lung cancer.

Citing Articles

Prognostic risk modeling of endometrial cancer using programmed cell death-related genes: a comprehensive machine learning approach.

Chen T, Yang Y, Huang Z, Pan F, Xiao Z, Gong K Discov Oncol. 2025; 16(1):280.

PMID: 40056247 PMC: 11890841. DOI: 10.1007/s12672-025-02039-8.

Nonylphenol promotes epithelial-mesenchymal transition in colorectal cancer cells by upregulating miR-151a-3p.

Wang B, Zhang N, Dai L, Zhang Y, Yin S, Yang X Discov Oncol. 2025; 16(1):63.

PMID: 39832042 PMC: 11747012. DOI: 10.1007/s12672-025-01805-y.

Molecular Profiling of A549 Cell-Derived Exosomes: Proteomic, miRNA, and Interactome Analysis for Identifying Potential Key Regulators in Lung Cancer.

Giannopoulos-Dimitriou A, Saiti A, Malousi A, Anagnostopoulos A, Vatsellas G, Al-Maghrabi P Cancers (Basel). 2025; 16(24.

PMID: 39766023 PMC: 11674491. DOI: 10.3390/cancers16244123.

New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies.

Xue M, Ma L, Zhang P, Yang H, Wang Z Int J Biol Sci. 2024; 20(14):5747-5763.

PMID: 39494330 PMC: 11528464. DOI: 10.7150/ijbs.100960.

In Silico Identification of Dysregulated miRNAs Targeting Gene in Pancreatic Cancer.

Garibaldi-Rios A, Figuera L, Zuniga-Gonzalez G, Gomez-Meda B, Garcia-Verdin P, Carrillo-Davila I Diseases. 2024; 12(7).

PMID: 39057123 PMC: 11276408. DOI: 10.3390/diseases12070152.

References

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

Distefano R, Nigita G, Le P, Romano G, Acunzo M, Nana-Sinkam P . Disparities in Lung Cancer: miRNA Isoform Characterization in Lung Adenocarcinoma. Cancers (Basel). 2022; 14(3). PMC: 8833952. DOI: 10.3390/cancers14030773. View

Lin E, Hsu J, Lee T, Hsu C, Lin T, Jan Y . Targeting cancer stemness mediated by BMI1 and MCL1 for non-small cell lung cancer treatment. J Cell Mol Med. 2022; 26(15):4305-4321. PMC: 9401641. DOI: 10.1111/jcmm.17453. View

Keith B, Johnson R, Simon M . HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12(1):9-22. PMC: 3401912. DOI: 10.1038/nrc3183. View

Zhou Y, Wang L, Sun Z, Zhang J, Wang X . Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance. Am J Cancer Res. 2021; 10(12):4251-4265. PMC: 7783754. View

Li N, Liu M, Cao X, Li W, Li Y, Zhao Z . Identification of differentially expressed genes using microarray analysis and COL6A1 induction of bone metastasis in non-small cell lung cancer. Oncol Lett. 2021; 22(4):693. PMC: 8358737. DOI: 10.3892/ol.2021.12954. View

Coleman R, Body J, Aapro M, Hadji P, Herrstedt J . Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3:iii124-37. DOI: 10.1093/annonc/mdu103. View

Xiong Q, Jiang L, Liu K, Jiang X, Liu B, Shi Y . miR-133b targets NCAPH to promote β-catenin degradation and reduce cancer stem cell maintenance in non-small cell lung cancer. Signal Transduct Target Ther. 2021; 6(1):252. PMC: 8260594. DOI: 10.1038/s41392-021-00555-x. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

10.

Liu J, Ren L, Li S, Li W, Zheng X, Yang Y . The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021; 11(9):2783-2797. PMC: 8463268. DOI: 10.1016/j.apsb.2021.01.001. View

11.

Zhao Y, Jin L, Zhang X . Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1. Aging (Albany NY). 2021; 13(14):18498-18514. PMC: 8351670. DOI: 10.18632/aging.203298. View

12.

Asplund A, Edqvist P, Schwenk J, Ponten F . Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics. 2012; 12(13):2067-77. DOI: 10.1002/pmic.201100504. View

13.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

14.

Song Y, Liu X, Wang F, Wang X, Cheng G, Peng C . Identification of Metastasis-Associated Biomarkers in Synovial Sarcoma Using Bioinformatics Analysis. Front Genet. 2020; 11:530892. PMC: 7518102. DOI: 10.3389/fgene.2020.530892. View

15.

Graminha A, Popolin C, de Araujo-Neto J, Correa R, de Oliveira K, Godoy L . New ruthenium complexes containing salicylic acid and derivatives induce triple-negative tumor cell death via the intrinsic apoptotic pathway. Eur J Med Chem. 2022; 243:114772. DOI: 10.1016/j.ejmech.2022.114772. View

16.

Brown J, Sim S . Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia. 2010; 12(9):685-96. PMC: 2933689. DOI: 10.1593/neo.10610. View

17.

Lee J, Ku B, Lim S, Lee M, Kim H, Kim M . The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol. 2015; 10(6):903-9. DOI: 10.1097/JTO.0000000000000535. View

18.

Hsu Y, Hung J, Chang W, Lin Y, Pan Y, Tsai P . Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017; 36(34):4929-4942. DOI: 10.1038/onc.2017.105. View

19.

Liao Y, Wang J, Jaehnig E, Shi Z, Zhang B . WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47(W1):W199-W205. PMC: 6602449. DOI: 10.1093/nar/gkz401. View

20.

Qian J, Hassanein M, Hoeksema M, Harris B, Zou Y, Chen H . The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci U S A. 2015; 112(11):3469-74. PMC: 4371932. DOI: 10.1073/pnas.1421975112. View